Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CDX-6114 in healthy volunteers
NCT03577886Phase 1Completed
- Sponsor
- Codexis, Inc.
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in phenylketonuria (PKU) comparing CDX-6114 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent Adverse Events at 22 days. Started Jul 2018; status: completed.
02
Drugs
CDX-6114
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT03577886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577886.